3.85

3.75% -0.15

After Hours: 3.85

Indaptus Therapeutics Inc (INDP)

Overview News Price History Financials Discussions Forecast

Indaptus Therapeutics Inc stock is traded at $3.85, with a volume of 569.45K. It is down -3.75% in the last 24 hours and up +251.60% over the past month. Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Previous Close:

$4.00

Open:

$3.995

24h Volume:

569.45K

Relative Volume:

0.76

Market Cap:

$512.98M

Revenue:

Net Income/Loss:

$-18.86M

P/E Ratio:

-0.2398

EPS:

-16.054

Net Cash Flow:

$-17.68M

1W Performance:

+8.45%

1M Performance:

+251.60%

6M Performance:

+118.75%

1Y Performance:

+17.38%

1-Day Range:

$3.46

$3.995

1-Week Range:

$2.90

$4.22

52-Week Range:

$0.92

$8.57

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name

Indaptus Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(646) 427-2727

Address

3 COLUMBUS CIRCLE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

INDP's Discussions on Twitter

Compare INDP vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDP Indaptus Therapeutics Inc	3.85	512.98M	0	-18.86M	-17.68M	-16.05
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Indaptus Therapeutics Inc Stock (INDP) Latest News

Sep 23, 2026

Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement - marketscreener.com

Sep 10, 2026

Form 8K Indaptus Therapeutics Inc For: 10 September By Investing.com - Investing.com South Africa

Sep 10, 2026

Form 8K Indaptus Therapeutics Inc For: 10 September - Investing.com India

Sep 10, 2026

Indaptus Therapeutics Raises $24 Million in Private Placement of 20.3M Shares - TradingView

Sep 10, 2026

Sep 08, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Sep 08, 2026

Indaptus Therapeutics Secures $100 Million At-The-Market Equity Facility - Minichart

Sep 08, 2026

Sep 07, 2026

Indaptus Therapeutics, Inc. announced that it expects to receive $23.999989 million in funding - marketscreener.com

Sep 07, 2026

Sep 04, 2026

Indaptus Therapeutics Announces Routine Board Member Resignation - TipRanks

Sep 04, 2026

Indaptus Therapeutics, Inc. Announces Resignation of Tim Ruan from Director, Effective September 2, 2026 - marketscreener.com

Sep 04, 2026

Indaptus Therapeutics (INDP) updates $100M stock sale plan - Stock Titan

Sep 04, 2026

Sep 02, 2026

INDP Q4 2025 Earnings: EPS Misses by 1.41% With No Revenue, But Shares Gain 0.88%Earnings Decline Risk - dars.gov.et

Sep 02, 2026

Sep 01, 2026

Indaptus Updates ATM Agreement to Expand Capital Flexibility - tipranks.com

Sep 01, 2026

Indaptus Therapeutics Launches $100 Million ATM Equity Program With H.C. Wainwright - TradingView

Sep 01, 2026

Indaptus sets up $100M at-the-market stock program - Stock Titan

Sep 01, 2026

Aug 31, 2026

Indaptus Therapeutics Launches $100M ATM Offering at $1.14 Per Share (NASDAQ: INDP) - Kalkine Media

Aug 31, 2026

Aug 26, 2026

Indaptus Therapeutics, Inc. SEC Filing (Aug 26, 2026) - Stock Titan

Aug 26, 2026

Aug 20, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Aug 20, 2026

Aug 14, 2026

Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us

Aug 14, 2026

Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine

Aug 14, 2026

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat

Aug 14, 2026

Aug 13, 2026

Indaptus Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026

Indaptus Therapeutics Q2 EPS beats estimate as loss narrows - scanx.trade

Aug 13, 2026

Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot - TipRanks

Aug 13, 2026

Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView

Aug 13, 2026

Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan

Aug 13, 2026

Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative

Aug 13, 2026

Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan

Aug 13, 2026

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Indaptus Therapeutics (INDP) Falls 14% to $1.02 — Biotech Micro-Cap Tests Critical SupportDescending Triangle - vinanet.vn

Aug 13, 2026

Aug 12, 2026